Tobin Schilke - 23 Feb 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CRNX
Reported as of: 23 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Feb 2026, 16:36:22 UTC
Prior SEC filing: 11 Mar 2025
Next SEC filing: 04 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke

Key filing fact

Tobin Schilke filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 25 Feb 2026.

Key facts

This page summarizes Tobin Schilke's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Feb 2026, 16:36.

Change

Previous filing in this sequence was filed on 11 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678984 Primary reporting owner

Schilke Tobin

Relationship: Chief Financial Officer
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke
Signature date: 25 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Award

Transaction value: $0
Shares: +32,000
Change %: +61%
Price: $0.000000
Shares after: 84,834
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRNX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 23 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $43.79
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.

Footnote F2

Includes 834 shares acquired under the Issuer's Employee Stock Purchase Plan.

Footnote F3

The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.